Endothelial dysfunction is a hallmark of diabetic vasculopathies. Although hyperglycemia is believed to be the culprit causing endothelial damage, the mechanism underlying early endothelial insult in prediabetes remains obscure. We used a nonobese high-calorie (HC)-fed rat model with hyperinsulinemia, hypercholesterolemia, and delayed development of hyperglycemia to unravel this mechanism. Compared with aortic rings from control rats, HC-fed rat rings displayed attenuated acetylcholinemediated relaxation. While sensitive to nitric oxide synthase (NOS) inhibition, aortic relaxation in HC-rat tissues was not affected by blocking the inward-rectifier potassium (Kir) channels using BaCl 2 . Although Kir channel expression was reduced in HC-rat aorta, Kir expression, endothelium-dependent relaxation, and the BaCl 2 -sensitive component improved in HC rats treated with atorvastatin to reduce serum cholesterol. Remarkably, HC tissues demonstrated increased reactive species (ROS) in smooth muscle cells, which was reversed in rats receiving atorvastatin. In vitro ROS reduction, with superoxide dismutase, improved endothelium-dependent relaxation in HC-rat tissues. Significantly, connexin-43 expression increased in HC aortic tissues, possibly allowing ROS movement into the endothelium and reduction of eNOS activity. In this context, gap junction blockade with 18-b-glycyrrhetinic acid reduced vascular tone in HC rat tissues but not in controls. This reduction was sensitive to NOS inhibition and SOD treatment, possibly as an outcome of reduced ROS influence, and emerged in BaCl 2 -treated control tissues. In conclusion, our results suggest that early metabolic challenge leads to reduced Kir-mediated endotheliumdependent hyperpolarization, increased vascular ROS potentially impairing NO synthesis and highlight these channels as a possible target for early intervention with vascular dysfunction in metabolic disease.
SIGNIFICANCE STATEMENTThe present study examines early endothelial dysfunction in metabolic disease. Our results suggest that reduced inwardrectifier potassium channel function underlies a defective endothelium-mediated relaxation possibly through alteration of nitric oxide synthase activity. This study provides a possible mechanism for the augmentation of relatively small changes in one endothelium-mediated relaxation pathway to affect overall endothelial response and highlights the potential role of inwardrectifier potassium channel function as a therapeutic target to treat vascular dysfunction early in the course of metabolic disease.
Diabetes remains a main risk factor for cardiovascular disorders. The vascular impact of diabetes is typically related to poor glycemic control. Yet, a significant proportion of diabetic patients present with microvascular complications at initial diagnosis, implicating a vascular insult early in the course of metabolic dysfunction. On the other hand, recent evidence suggests that some anti‐diabetic drugs might have a positive impact on diabetic cardiovascular complications apart from their hypoglycemic effect. The mechanism of the early insult occurring in the context of diabetes development is not well‐defined. Furthermore, the potential corrective mechanism of anti‐diabetic drugs was not properly investigated in these circumstances. To address these questions, we developed a high calorie diet (HC)‐fed rat model with delayed development of hyperglycemia. Twelve weeks of feeding were not associated with an increase in neither body weight, blood pressure, blood glucose level, nor plasma insulin levels. Yet, HC‐fed rats showed an increased sensitivity to the pressor effect of phenylephrine together with an increased vascular contractile response evident in aortic segments and mesenteric micro‐vessels. This increased contractility was resistant to calcium‐free physiological solutions implicating a potential upregulation of calcium sensitization mechanisms. This observation was supported functionally whereby the isolated vessel segments showed an increased dependence on Rho‐associated kinase (ROCK) for the induced contraction. While there was no detected increase in ROCK expression, western blotting for phosphorylated MYPT1 showed an increased basal activity in vessels from HC‐fed rats. This was associated with an elevated level of reactive oxygen species as detected by DHE staining. We believe that these abnormalities are brought around by increased TGF‐b expression as a consequence of peri‐vascular adipose tissue inflammation. TGF‐b and Smad3 staining were increased in vascular tissue from HC fed rats. This was also coupled with a reduction and an elevation of AMPK and Erk1/2 phosphorylation, respectively. Furthermore, TGF‐b and IL‐1b mRNA levels were elevated, together with observed areas of macrophage infiltration, in the peri‐vascular adipose tissue dissected from these vessel segments. A detrimental systemic response to HC feeding was ruled out, since there was no increase in neither serum TGF‐b nor advanced glycated end products. Oral treatment with metformin or pioglitazone for the last two weeks of feeding; or switching to normal diet for the same duration were associated with a decrease in markers of adipose inflammation and a reversal of all functional and molecular abnormalities observed in HC‐fed rats. As such, it is likely that early vascular dysfunction in the course of diabetes results as a consequence of peri‐vascular adipose inflammation and could potentially be modified at the early stage by anti‐diabetic drugs with known anti‐inflammatory potential.Support or Funding InformationSupported by AUB MPP fund #320148This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.